Androisoxazole
From Wikipedia, the free encyclopedia
| Clinical data | |
|---|---|
| Trade names | Neo-Ponden, Neo-Pondus |
| Routes of administration |
Oral |
| Identifiers | |
| Synonyms | 17α-Methyl-5α-androstano[3,2-c]isoxazol-17β-ol |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C21H31NO2 |
| Molar mass | 329.476 g/mol |
| 3D model (JSmol) | |
|
|
|
|
| (verify) | |
Androisoxazole (brand names Neo-Ponden, Neo-Pondus), also known as 17α-methyl-5α-androstano[3,2-c]isoxazol-17β-ol, is an orally active anabolic-androgenic steroid (AAS) and a 17α-alkylated derivative of dihydrotestosterone (DHT) that is marketed in Spain and Italy.[1][2][3][4] It is closely related to stanozolol, differing only in having an isoxazole instead of pyrazole ring fused to the A ring,[4] and is also related to furazabol, prostanozol, and danazol.
References[edit]
- ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 63–. ISBN 978-3-88763-075-1.
- ^ Charles D. Kochakian (6 December 2012). Anabolic-Androgenic Steroids. Springer Science & Business Media. pp. 384–. ISBN 978-3-642-66353-6.
- ^ ANTONINI FM, VERDI G (October 1961). "[Preliminary results of experience with a new anabolic steroid, "androisoxazole," in the aged.]". Minerva Medica (in Italian). 52: 3437–41. PMID 13861810.
- ^ a b ARNOLD A, POTTS GO, BEYLER AL (December 1963). "RELATIVE ORAL ANABOLIC TO ANDROGENIC ACTIVITY RATIOS OF ANDROISOXAZOLE, ETHYLESTRENOL, METHYLANDROSTENOLISOXAZOLE AND TESTOSTERONE". Acta Endocrinologica. 44: 490–8. PMID 14082537.
| This article about a steroid is a stub. You can help Wikipedia by expanding it. |
| This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |